EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Molecular characterization of Streptococcus pneumoniae causing disease among children in Nigeria during the introduction of PCV10 (GSK)

Stephanie W Lo, Paulina A Hawkins, Binta Jibir, Fatimah Hassan-Hanga, Mahmoud Gambo, Rasaq Olaosebikan, Grace Olanipekun, Huda Munir, Nicholas Kocmich, Amy Rezac-Elgohary, Safiya Gambo, Danstan Bagenda und 6 weitere

Microbial Genomics · 2023

DOI: 10.1099/mgen.0.001094 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Microbial Genomics, 2023. Verfasst von Stephanie W Lo und 17 weiteren Autor:innen. Beteiligte Einrichtung: Parasites and Microbes, Wellcome Sanger Institute, Hinxton, UK. Hauptthemen laut MEDLINE: Pneumococcal Infections, Anemia, Sickle Cell. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Wellcome Trust, Bill and Melinda Gates Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Streptococcus pneumoniae ( pneumococcus ) is a leading vaccine-preventable cause of childhood invasive disease. Nigeria has the second highest pneumococcal disease burden globally, with an estimated ~49 000 child deaths caused by pneumococcal infections each year. Ten-valent pneumococcal conjugate vaccine (GSK; PCV10) was introduced in December 2014 in a phased approach. However, few studies have characterized the disease-causing pneumococci from Nigeria. This study assessed the prevalence of serotypes, antibiotic susceptibility and genomic lineages using whole genome sequencing and identified lineages that could potentially escape PCV10 (GSK). We also investigated the potential differences in pneumococcal lineage features between children with and without sickle cell disease. A collection of 192 disease-causing pneumococcal isolates was obtained from Kano ( n =189) and Abuja ( n =3) states, Nigeria, between 1 January 2014 and 31 May 2018. The majority (99 %, 190/192) of specimens were recovered from children aged 5 years or under. Among them, 37 children had confirmed or traits of sickle cell disease. Our findings identified 25 serotypes expressed by 43 Global Pneumococcal Sequence Clusters (GPSCs) and 85 sequence types (STs). The most common serotypes were 14 (18 %, n =35), 6B (16 %, n =31), 1 (9 %, n =17), 5 (9 %, n =17) and 6A (9 %, n =17); all except serotype 6A are included in PCV10 (GSK). PCV10 (SII; PNEUMOSIL) and PCV13 formulations include serotypes 6A and 19A which would increase the overall coverage from 67 % by PCV10 (GSK) to 78 and 82 %, respectively. The pneumococcal lineages were a mix of globally spreading and unique local lineages. Following the use of PCV10 (GSK), GPSC5 expressing serotype 6A, GPSC10 (19A), GPSC26 (12F and 46) and GPSC627 (9L) are non-vaccine type lineages that could persist and potentially expand under vaccine-selective pressure. Approximately half (52 %, 99/192) of the pneumococcal isolates were resistant to the first-line antibiotic penicillin and 44 % (85/192) were multidrug-resistant. Erythromycin resistance was very low (2 %, 3/192). There was no significant difference in clinical manifestation, serotype prevalence or antibiotic resistance between children with and without traits of or confirmed sickle cell disease. In summary, our findings show that a high percentage of the pneumococcal disease were caused by the serotypes that are covered by currently available vaccines. Given the low prevalence of resistance, macrolide antibiotics, such as erythromycin, should be considered as an option to treat pneumococcal disease in Nigeria. However, appropriate use of macrolide antibiotics should be vigilantly monitored to prevent the potential increase in macrolide resistance.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pneumococcal InfectionsAnemia, Sickle CellHumansChildStreptococcus pneumoniaeNigeriaAnti-Bacterial AgentsDrug Resistance, BacterialMacrolidesErythromycinProtein Synthesis InhibitorsPneumococcal Vaccines

Stichwörter der Autor:innen

NigeriaPneumococcigenomicspneumococcal conjugate vaccine

Substanzen

Anti-Bacterial AgentsMacrolidesErythromycinProtein Synthesis Inhibitors10-valent pneumococcal conjugate vaccinePneumococcal Vaccines

Autor:innen und Institutionen

  • Parasites and Microbes, Wellcome Sanger Institute, Hinxton, UK.
  • Centers for Disease Control and Prevention, Atlanta, GA, USA.
  • Hasiya Bayero Pediatric Hospital, Kano, Nigeria.
  • Aminu Kano Teaching Hospital, Kano, Nigeria.
  • Department of Pharmacology and Experimental Therapeutics, Thomas Jefferson University, Philadelphia, PA, USA.
  • International Foundation against Infectious Diseases in Nigeria, Abuja, Nigeria.

Förderung

  • Wellcome Trust
  • Bill and Melinda Gates Foundation

Zitieren

APA

Lo, S. W., Hawkins, P. A., Jibir, B., Hassan-Hanga, F., Gambo, M., Olaosebikan, R., Olanipekun, G., Munir, H., Kocmich, N., Rezac-Elgohary, A., Gambo, S., Bagenda, D., Fey, P., Breiman, R. F., McGee, L., Bentley, S. D., Obaro, S. K., & Community Acquired Pneumonia and Invasive Bacterial Disease (CAPIBD) Consortium (2023). Molecular characterization of Streptococcus pneumoniae causing disease among children in Nigeria during the introduction of PCV10 (GSK). Microbial Genomics. https://doi.org/10.1099/mgen.0.001094

Vancouver

Lo SW, Hawkins PA, Jibir B, Hassan-Hanga F, Gambo M, Olaosebikan R, et al. Molecular characterization of Streptococcus pneumoniae causing disease among children in Nigeria during the introduction of PCV10 (GSK). Microbial Genomics. 2023. doi:10.1099/mgen.0.001094

BibTeX
@article{Lo2023,
  author = {Lo, Stephanie W and Hawkins, Paulina A and Jibir, Binta and Hassan-Hanga, Fatimah and Gambo, Mahmoud and Olaosebikan, Rasaq and Olanipekun, Grace and Munir, Huda and Kocmich, Nicholas and Rezac-Elgohary, Amy and Gambo, Safiya and Bagenda, Danstan and Fey, Paul and Breiman, Robert F and McGee, Lesley and Bentley, Stephen D and Obaro, Stephen K and Community Acquired Pneumonia and Invasive Bacterial Disease (CAPIBD) Consortium, Community Acquired Pneumonia and Invasive Bacterial Disease (CAPIBD) Consortium},
  title = {Molecular characterization of Streptococcus pneumoniae causing disease among children in Nigeria during the introduction of PCV10 (GSK)},
  journal = {Microbial Genomics},
  year = {2023},
  doi = {10.1099/mgen.0.001094}
}
Kostenlos starten →